148 related articles for article (PubMed ID: 21521416)
21. Temsirolimus, an mTOR inhibitor for treatment of patients with advanced renal cell carcinoma.
Malizzia LJ; Hsu A
Clin J Oncol Nurs; 2008 Aug; 12(4):639-46. PubMed ID: 18676330
[TBL] [Abstract][Full Text] [Related]
22. mTOR inhibitors show promising in vitro activity in bladder cancer and head and neck squamous cell carcinoma.
Schedel F; Pries R; Thode B; Wollmann B; Wulff S; Jocham D; Wollenberg B; Kausch I
Oncol Rep; 2011 Mar; 25(3):763-8. PubMed ID: 21240463
[TBL] [Abstract][Full Text] [Related]
23. Antitumor activity of hydrophilic Paclitaxel copolymer prodrug using locoregional delivery in human orthotopic non-small cell lung cancer xenograft models.
Zou Y; Fu H; Ghosh S; Farquhar D; Klostergaard J
Clin Cancer Res; 2004 Nov; 10(21):7382-91. PubMed ID: 15534115
[TBL] [Abstract][Full Text] [Related]
24. Concurrent and sequential administration of chemotherapy and the Mammalian target of rapamycin inhibitor temsirolimus in human cancer cells and xenografts.
Fung AS; Wu L; Tannock IF
Clin Cancer Res; 2009 Sep; 15(17):5389-95. PubMed ID: 19706800
[TBL] [Abstract][Full Text] [Related]
25. Temsirolimus for metastatic desmoplastic small round cell tumor.
Thijs AM; van der Graaf WT; van Herpen CM
Pediatr Blood Cancer; 2010 Dec; 55(7):1431-2. PubMed ID: 20730888
[TBL] [Abstract][Full Text] [Related]
26. A Phase 1 clinical study of temsirolimus (CCI-779) in Japanese patients with advanced solid tumors.
Fujisaka Y; Yamada Y; Yamamoto N; Horiike A; Tamura T
Jpn J Clin Oncol; 2010 Aug; 40(8):732-8. PubMed ID: 20430774
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of induced autophagy increases apoptosis of Nara-H cells.
Nakamura O; Hitora T; Akisue T; Kawamoto T; Yamagami Y; Yamamoto T
Int J Oncol; 2011 Dec; 39(6):1545-52. PubMed ID: 21805033
[TBL] [Abstract][Full Text] [Related]
28. The effect of thalidomide on non-small cell lung cancer (NSCLC) cell lines: possible involvement in the PPARgamma pathway.
DeCicco KL; Tanaka T; Andreola F; De Luca LM
Carcinogenesis; 2004 Oct; 25(10):1805-12. PubMed ID: 15205358
[TBL] [Abstract][Full Text] [Related]
29. Marked antiangiogenic and antitumor efficacy of AG3340 in chemoresistant human non-small cell lung cancer tumors: single agent and combination chemotherapy studies.
Shalinsky DR; Brekken J; Zou H; Bloom LA; McDermott CD; Zook S; Varki NM; Appelt K
Clin Cancer Res; 1999 Jul; 5(7):1905-17. PubMed ID: 10430098
[TBL] [Abstract][Full Text] [Related]
30. The role of mTOR inhibitors in the inhibition of growth and cortisol secretion in human adrenocortical carcinoma cells.
De Martino MC; van Koetsveld PM; Feelders RA; Sprij-Mooij D; Waaijers M; Lamberts SW; de Herder WW; Colao A; Pivonello R; Hofland LJ
Endocr Relat Cancer; 2012 Jun; 19(3):351-64. PubMed ID: 22420007
[TBL] [Abstract][Full Text] [Related]
31. Cyclooxygenase-2 inhibitor, nimesulide, improves radiation treatment against non-small cell lung cancer both in vitro and in vivo.
Grimes KR; Warren GW; Fang F; Xu Y; St Clair WH
Oncol Rep; 2006 Oct; 16(4):771-6. PubMed ID: 16969492
[TBL] [Abstract][Full Text] [Related]
32. Hypoxia-induced resistance to cisplatin and doxorubicin in non-small cell lung cancer is inhibited by silencing of HIF-1alpha gene.
Song X; Liu X; Chi W; Liu Y; Wei L; Wang X; Yu J
Cancer Chemother Pharmacol; 2006 Dec; 58(6):776-84. PubMed ID: 16532342
[TBL] [Abstract][Full Text] [Related]
33. [Treatment of the unresectable non small cell lung carcinoma].
Spásová I
Cas Lek Cesk; 2005; 144(9):602-12; discussion 612-3. PubMed ID: 16193938
[TBL] [Abstract][Full Text] [Related]
34. AKT/mTOR pathway activation and BCL-2 family proteins modulate the sensitivity of human small cell lung cancer cells to RAD001.
Marinov M; Ziogas A; Pardo OE; Tan LT; Dhillon T; Mauri FA; Lane HA; Lemoine NR; Zangemeister-Wittke U; Seckl MJ; Arcaro A
Clin Cancer Res; 2009 Feb; 15(4):1277-87. PubMed ID: 19228731
[TBL] [Abstract][Full Text] [Related]
35. Schedule-dependent synergism of vinorelbine and 5-fluorouracil/UFT against non-small cell lung cancer.
Matsumoto S; Igishi T; Hashimoto K; Kodani M; Shigeoka Y; Nakanishi H; Touge H; Kurai J; Makino H; Takeda K; Yasuda K; Hitsuda Y; Shimizu E
Int J Oncol; 2004 Nov; 25(5):1311-8. PubMed ID: 15492820
[TBL] [Abstract][Full Text] [Related]
36. Acquisition of an enhanced aggressive phenotype in human lung cancer cells selected by suboptimal doses of cisplatin following cell deattachment and reattachment.
Hsieh JL; Lu CS; Huang CL; Shieh GS; Su BH; Su YC; Lee CH; Chang MY; Wu CL; Shiau AL
Cancer Lett; 2012 Aug; 321(1):36-44. PubMed ID: 22450752
[TBL] [Abstract][Full Text] [Related]
37. Histone deacetylase inhibitors suppress the inducibility of nuclear factor-kappaB by tumor necrosis factor-alpha receptor-1 down-regulation.
Imre G; Gekeler V; Leja A; Beckers T; Boehm M
Cancer Res; 2006 May; 66(10):5409-18. PubMed ID: 16707469
[TBL] [Abstract][Full Text] [Related]
38. Enhanced efficacy of a novel controlled release paclitaxel formulation (PACLIMER delivery system) for local-regional therapy of lung cancer tumor nodules in mice.
Harper E; Dang W; Lapidus RG; Garver RI
Clin Cancer Res; 1999 Dec; 5(12):4242-8. PubMed ID: 10632366
[TBL] [Abstract][Full Text] [Related]
39. Synergistic effects of histone deacetylase inhibitor in combination with mTOR inhibitor in the treatment of prostate carcinoma.
Thelen P; Krahn L; Bremmer F; Strauss A; Brehm R; Loertzer H
Int J Mol Med; 2013 Feb; 31(2):339-46. PubMed ID: 23292124
[TBL] [Abstract][Full Text] [Related]
40. Analysis of the pharmacodynamic activity of the mTOR inhibitor ridaforolimus (AP23573, MK-8669) in a phase 1 clinical trial.
Berk L; Mita MM; Kreisberg J; Bedrosian CL; Tolcher AW; Clackson T; Rivera VM
Cancer Chemother Pharmacol; 2012 May; 69(5):1369-77. PubMed ID: 22231376
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]